Literature DB >> 7524640

Decreased surface IgM receptor-mediated activation of phospholipase C gamma 2 in B-1 lymphocytes.

D L Morris1, T L Rothstein.   

Abstract

Intracellular signaling triggered by the antigen receptor of primary B-1 (CD5+ B) lymphocytes is insufficient to bring about cell cycle progression to S phase; this appears to result from a block in signal propagation prior to the activation of protein kinase C. The present studies were undertaken to evaluate specific elements in the proximal portion of the intracellular signaling cascade to determine the basis for aberrant signal transduction in B-1 cells. There was no evidence for an alteration in src kinase composition or for diminished receptor mediated tyrosine phosphorylation on the part of B-1 cells. Further, phospholipase C gamma 2 was inducibly tyrosine phosphorylated following surface Ig ligation. However, the receptor mediated increase in enzymatic activity of immunoprecipitated phospholipase C gamma 2 was markedly diminished in B-1 as compared with B-2 cells. These results indicate that phospholipase C gamma 2 largely fails to become activated following surface Ig receptor interaction in B-1 cells and suggest that this enzyme may be directly involved in controlling the propagation of progression signals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7524640     DOI: 10.1093/intimm/6.7.1011

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  12 in total

Review 1.  Cell cycle control mechanisms in B-1 and B-2 lymphoid subsets.

Authors:  Michael J Piatelli; Debra Tanguay; Thomas L Rothstein; Thomas C Chiles
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

2.  Regulation of B-1 cell activation and its autoantibody production by Lyn kinase-regulated signallings.

Authors:  H Ochi; H Takeshita; T Suda; S Nisitani; T Honjo; T Watanabe
Journal:  Immunology       Date:  1999-12       Impact factor: 7.397

3.  FCRL5 exerts binary and compartment-specific influence on innate-like B-cell receptor signaling.

Authors:  Zilu Zhu; Ran Li; Hao Li; Tong Zhou; Randall S Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

4.  Murine B1 B cells require IL-5 for optimal T cell-dependent activation.

Authors:  L D Erickson; T M Foy; T J Waldschmidt
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

5.  Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells.

Authors:  Nichol E Holodick; Joseph R Tumang; Thomas L Rothstein
Journal:  Mol Immunol       Date:  2009-07-09       Impact factor: 4.407

6.  Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling.

Authors:  Shih-Shih Chen; Franak Batliwalla; Nichol E Holodick; Xiao-Jie Yan; Sophia Yancopoulos; Carlo M Croce; Thomas L Rothstein; Nicholas Chiorazzi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-02       Impact factor: 11.205

7.  Autoreactive B cells discriminate CpG-rich and CpG-poor DNA and this response is modulated by IFN-alpha.

Authors:  Melissa B Uccellini; Liliana Busconi; Nathaniel M Green; Patricia Busto; Sean R Christensen; Mark J Shlomchik; Ann Marshak-Rothstein; Gregory A Viglianti
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

Review 8.  Human B-1 cells take the stage.

Authors:  Thomas L Rothstein; Daniel O Griffin; Nichol E Holodick; Tam D Quach; Hiroaki Kaku
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

9.  Early induction of cyclin D2 expression in phorbol ester-responsive B-1 lymphocytes.

Authors:  D A Tanguay; T P Colarusso; S Pavlovic; M Irigoyen; R G Howard; J Bartek; T C Chiles; T L Rothstein
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  A CD25⁻ positive population of activated B1 cells expresses LIFR and responds to LIF.

Authors:  Joseph R Tumang; Nichol E Holodick; Teresa C Vizconde; Hiroaki Kaku; Rubén Francés; Thomas L Rothstein
Journal:  Front Immunol       Date:  2011-03-21       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.